Primary lymphomas of the genitourinary tract: A population-based study.
Bladder lymphoma
Genitourinary
Genitourinary neoplasm
Primary extranodal lymphoma
Prostate lymphoma
Renal lymphoma
Survival
Testis lymphoma
Journal
Asian journal of urology
ISSN: 2214-3882
Titre abrégé: Asian J Urol
Pays: Singapore
ID NLM: 101699720
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
17
04
2019
revised:
14
06
2019
accepted:
01
07
2019
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
1
10
2020
Statut:
ppublish
Résumé
We performed a population-based analysis focusing on primary extranodal lymphoma of either testis, kidney, bladder or prostate (PGUL). We identified all cases of localized testis, renal, bladder and prostate primary lymphomas (PL) versus primary testis, kidney, bladder and prostate cancers within the Surveillance, Epidemiology, and End Results database (1998-2015). Estimated annual proportion change methodology (EAPC), multivariable logistic regression models, cumulative incidence plots and multivariable competing risks regression models were used. The rates of testis-PL, renal-PL, bladder-PL and prostate-PL were 3.04%, 0.22%, 0.18% and 0.01%, respectively. Patients with PGUL were older and more frequently Caucasian. Annual rates significantly decreased for renal-PL (EAPC: -5.6%; PGUL rates are extremely low and on the decrease in kidney and prostate but stable in testis and bladder. Relative to primary genitourinary tumors, PGUL are associated with worse CSM for testis-PL and renal-PL but not for bladder-PL and prostate-PL, even after adjustment for other-cause mortality.
Identifiants
pubmed: 32995277
doi: 10.1016/j.ajur.2019.11.002
pii: S2214-3882(19)30112-2
pmc: PMC7498952
doi:
Types de publication
Journal Article
Langues
eng
Pagination
332-339Informations de copyright
© 2020 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Ecancermedicalscience. 2017 Dec 12;11:789
pubmed: 29290758
J Clin Oncol. 2009 Nov 1;27(31):5227-32
pubmed: 19770371
Chin Clin Oncol. 2015 Mar;4(1):10
pubmed: 25841717
Crit Rev Oncol Hematol. 2008 Feb;65(2):183-9
pubmed: 17962036
J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51
pubmed: 10922409
Ann Hematol. 2005 Jan;84(1):1-12
pubmed: 15480663
Lancet. 2017 Jul 15;390(10091):298-310
pubmed: 28153383
Biometrics. 2006 Sep;62(3):847-54
pubmed: 16984328
Anticancer Res. 2017 Dec;37(12):6989-6995
pubmed: 29187485
Blood. 2014 Jan 23;123(4):486-93
pubmed: 24282217
J Ultrasound Med. 2015 Jun;34(6):1139-45
pubmed: 26014335
Urol Ann. 2018 Jul-Sep;10(3):249-253
pubmed: 30089981
AJR Am J Roentgenol. 2013 Nov;201(5):W712-9
pubmed: 24147501